Icotrokinra sustained skin clearance in patients with plaque psoriasis through two years of treatment, according to long-term results from the ICONIC-LEAD trial reported by HCPLive.

The two-year mark is the headline: patients who achieved clearance on the oral selective interleukin-23 receptor antagonist maintained that response into the second year of therapy. For a field where durability data increasingly drive formulary and switching decisions, sustained clearance at 24 months positions icotrokinra alongside — and in oral form, potentially ahead of — injectable biologics in the durability conversation.

What is icotrokinra?

Icotrokinra is an orally active small molecule that blocks the IL-23 receptor, a target already validated in psoriasis by injectable anti-p21 and anti-IL-23 monoclonal antibodies. The drug is designed to reproduce the pathway-specific efficacy of that biologic class without requiring injections — a delivery advantage that matters for adherence in chronic plaque psoriasis care.

What does the 2-year ICONIC-LEAD data show?

The new analysis reports maintenance of skin clearance at the two-year timepoint in trial participants continuing icotrokinra. Dermatology clinicians tracking the agent will read the data through two practical lenses:

• Durability: sustained clearance at 24 months addresses the most common real-world failure mode of psoriasis therapy — response decay over time.
• Tolerability over the long arc: two-year exposure data are the threshold payers and regulators weigh when positioning an oral against established biologics.

HCPLive's report frames the ICONIC-LEAD long-term extension results as evidence that the clearance achieved in earlier phases of the program holds up with continued dosing.

Why durability data move the market

Psoriasis treatment guidelines and payers increasingly demand sustained-response evidence before granting preferred access, particularly for oral agents entering a market dominated by TNF, IL-17 and IL-23 inhibitors. Two-year clearance data from a registrational program strengthen the case for icotrokinra as a first-line oral option rather than a step-therapy afterthought — assuming regulators concur.

The open question for practice is how the long-term safety profile and comparative effectiveness stack up against IL-23 biologics head to head, and whether the durability seen in the trial setting translates to routine care, where adherence is less controlled. Full publication of the ICONIC-LEAD two-year dataset — including PASI response rates and safety tables — will determine whether icotrokinra's oral convenience comes with biologic-grade staying power.